Developing androgen receptor targeting for salivary gland cancers

Salivary gland cancers (SGCs) are rare malignancies that can arise from major (parotid, submandibular, sublingual) or minor glands present throughout the upper aerodigestive tract. These tumors encompass a diverse set of diseases representing more than 20 different histologic subtypes with distinct clinical behaviors, genomic/molecular profiles, and responsiveness to drug therapy [1–3]. Similar to other rare diseases, the lack of prospective drug trials focused on singular SGC tumor types makes evidence-based management a challenge.